Meeting
2013 Gastrointestinal Cancers Symposium
Safety and efficacy during first line with cetuximab in KRAS wild-type metastatic colorectal cancer (mCRC): Results of a large prospective multicenter cohort carried out by the premium French observational study.
Authors
Laurent Mineur
Institut Sainte Catherine
Laurent Mineur , Gilles Seni , Laurent Miglianico , louis-Marie Dourthe , Nathalie Bonichon , Lionel Moreau , Rosine Guimbaud , Denis Smith , Emmanuel Achille , Robert Herve , Jean Michel Bons , Stephane Remy , jean Pierre Daures
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Cancers of the Colon and Rectum
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 31, 2013 (suppl 4; abstr555)
DOI
10.1200/jco.2013.31.4_suppl.555
Abstract #
555
Poster Bd #
E3
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
Efficacy of chemotherapy plus cetuximab according to metastatic site in KRAS wild-type metastatic colorectal cancer (mCRC): Analysis of CRYSTAL and OPUS studies.
First Author: C. Kohne
Poster
2020 Gastrointestinal Cancers Symposium
Treatment of metastatic colorectal cancer (mCRC) according to age.
First Author: Laura Ortega
Poster
2019 Gastrointestinal Cancers Symposium
Updated results of the BEACON CRC safety lead-in: Encorafenib (ENCO) + binimetinib (BINI) + cetuximab (CETUX) for BRAFV600E-mutant metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz
Poster
2016 ASCO Annual Meeting
MAVERICC, a phase II study of mFOLFOX6-bevacizumab (BV) vs FOLFIRI-BV as first-line (1L) chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC): Outcomes by tumor location and KRAS status.
First Author: Heinz-Josef Lenz